MRUS
Price:
$42.45
Market Cap:
$2.91B
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients ...[Read more]
Industry
Biotechnology
IPO Date
2016-05-19
Stock Exchange
NASDAQ
Ticker
MRUS
According to Merus N.V.’s latest financial reports and current stock price. The company's current ROE is -45.38%. This represents a change of 280.93% compared to the average of -11.91% of the last 4 quarters.
The mean historical ROE of Merus N.V. over the last ten years is -15.39%. The current -45.38% ROE has changed 194.79% with respect to the historical average. Over the past ten years (40 quarters), MRUS's ROE was at its highest in in the December 2014 quarter at 147.34%. The ROE was at its lowest in in the December 2016 quarter at -90.19%.
Average
-15.39%
Median
-48.29%
Minimum
-152.63%
Maximum
489.15%
Discovering the peaks and valleys of Merus N.V. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 151.31%
Maximum Annual ROE = 489.15%
Minimum Annual Increase = -478.27%
Minimum Annual ROE = -152.63%
Year | ROE | Change |
---|---|---|
2023 | -43.48% | -18.12% |
2022 | -53.10% | 151.31% |
2021 | -21.13% | -74.73% |
2020 | -83.62% | 99.08% |
2019 | -42.00% | 59.01% |
2018 | -26.42% | -82.69% |
2017 | -152.63% | 9.98% |
2016 | -138.78% | 69.42% |
2015 | -81.92% | -116.75% |
2014 | 489.15% | -478.27% |
The current ROE of Merus N.V. (MRUS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-39.24%
5-year avg
-48.67%
10-year avg
-15.39%
Merus N.V.’s ROE is greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Adagene Inc. (-50.10%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.95%), greater than AnaptysBio, Inc. (-287.94%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Crinetics Pharmaceuticals, Inc. (-36.12%), less than Inhibrx Biosciences, Inc. (1.45%), greater than Lyell Immunopharma, Inc. (-34.64%), greater than Kronos Bio, Inc. (-64.55%), greater than Kura Oncology, Inc. (-44.09%), less than Protagonist Therapeutics, Inc. (34.68%), greater than Replimune Group, Inc. (-53.12%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Vaxcyte, Inc. (-23.53%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than Syndax Pharmaceuticals, Inc. (-64.34%), greater than Sutro Biopharma, Inc. (-97.01%),
Company | ROE | Market cap |
---|---|---|
-184.40% | $32.42M | |
-50.10% | $83.23M | |
-47.95% | $198.03M | |
-287.94% | $425.09M | |
-55.92% | $600.21M | |
-36.12% | $5.00B | |
1.45% | $209.47M | |
-34.64% | $179.85M | |
-64.55% | $57.32M | |
-44.09% | $695.21M | |
34.68% | $2.42B | |
-53.12% | $929.70M | |
-98.94% | $8.19B | |
-23.53% | $10.85B | |
-35.87% | $252.67M | |
-64.34% | $1.14B | |
-97.01% | $154.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Merus N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Merus N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Merus N.V.'s ROE?
How is the ROE calculated for Merus N.V. (MRUS)?
What is the highest ROE for Merus N.V. (MRUS)?
What is the 3-year average ROE for Merus N.V. (MRUS)?
What is the 5-year average ROE for Merus N.V. (MRUS)?
How does the current ROE for Merus N.V. (MRUS) compare to its historical average?